Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adc Therapeutics Sa (NY: ADCT )

0.7235 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.7235
Bid (Size) 0.6603 (30)
Ask (Size) 0.7235 (1)
Prev. Close 0.7235
Today's Range 0.7235 - 0.7235
52wk Range 0.3599 - 5.750
Shares Outstanding 76,721,543
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyst Expectations for ADC Therapeutics's Future
Via Benzinga
ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards
From ADC Therapeutics SA
Via GlobeNewswire

Performance

YTD
-79.85%
-79.85%
1 Month
+2.90%
+2.90%
3 Month
-42.12%
-42.12%
6 Month
-68.27%
-68.27%
1 Year
-78.72%
-78.72%

More News

Read More
ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via GlobeNewswire
Why BEST Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
The Latest Analyst Ratings for ADC Therapeutics
Via Benzinga
A Preview Of ADC Therapeutics's Earnings
Via Benzinga
4 Analysts Have This to Say About ADC Therapeutics
Via Benzinga
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics to Participate in September Investor Conferences
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)
From ADC Therapeutics SA
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
Via Benzinga
ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
From ADC Therapeutics SA
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
From ADC Therapeutics SA
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
ADC Therapeutics Pulls Plug On Mid-Stage Zynlonta Study In Untreated Lymphoma Patients After Patient Deaths
Via Benzinga
ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
From ADC Therapeutics SA
Via GlobeNewswire
Dow Rises More Than 200 Points; Adial Pharmaceuticals Shares Spike Higher
Via Benzinga
Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Crude Oil Rises 2%; ADC Therapeutics Shares Plummet
Via Benzinga
Dow Jumps Over 100 Points; US Small Business Optimism Index Tops Estimates
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.